Repositioning Candidate Details
| Candidate ID: | R0931 |
| Source ID: | DB06149 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Teicoplanin |
| Synonyms: | Teichomycin A2; Teicoplanin |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety. |
| CAS Number: | 61036-62-2 |
| Molecular Weight: | |
| DrugBank Indication: | For the treatment of bacterial infections caused by susceptible microorganisms. |
| DrugBank Pharmacology: | It is a glycopeptide antiobiotic extracted from <i>Actinoplanes teichomyceticus</i>, with a similar spectrum of activity to vancomycin. Its mechanism of action is to inhibit bacterial cell wall synthesis. Oral teicoplanin has been demonstrated to be effective in the treatment of pseudomembranous colitis and Clostridium difficile-associated diarrhoea, with comparable efficacy to vancomycin. |
| DrugBank MoA: | Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death. |
| Targets: | D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|